TrialBlood neoplasia2025

A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia.

Ahmed Aribi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.